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ABSTRACT 
  
 A “substantial evidence” of effectiveness is required for new cancer treatment regimens 
to be approved. Objective tumor shrinkage/enlargement has been adopted as an indicator of 
drugs efficacy. The change of tumor size is assessed and quantified by various radiological 
techniques; most commonly computed tomography (CT). A high accuracy and reproducibility 
is, for obvious reasons, necessary in order to achieve a meaningful evaluation of such studies. 
For that purpose, the World Health Organization criteria (WHO-criteria) were launched in 1979 
followed by the Response Evaluation Criteria In Solid Tumors (RECIST) in 2000 and the 
updated version RECIST 1.1 in 2009. There are, however, still several steps that may 
deteriorate consistencies.   
 The purpose of this thesis was to investigate causes that may affect inconsistency in 
evaluation procedure according to RECIST (study I and II) and to explore the percentage of 
tumor size change at the first follow-up CT as the potential new surrogate indicators for OS in 
patient with metastatic colorectal cancer (mCRC) (study III) and in patient with metastatic 
breast cancer (MBC) (study IV). 
 The number of discordant cases increased gradually when assessing fewer target 
lesions. Measuring fewer than four target lesions might cause discrepancies when more than 
five target lesions were present (study I). Interobserver variation using RECIST and WHO-
criteria were moderate: 0.53 (95%CI 0.33 - 0.72) and 0.60 (0.39 – 0.80), respectively. 
Intraobserver variation using RECIST and WHO-criteria were substantial to perfect that ranged 
between 0.76 – 0.96 and 0.86 – 0.91, respectively (study II). 
The initial change in tumor size 8 weeks after initiation of chemotherapy was prognostic for 
PFS: Hazard Ratio (HR) 2.21, 95%CI 1.97 – 2.49, and OS: HR2.01, 95%CI 1.75 – 2.31, in 
mCRC (study III). The initial change in tumor size also correlated with OS in MBC (study IV). 
A marked difference in OS between patients with or without new lesion was demonstrated in 
mCRC: HR 3.77, 95%CI 2.08 – 6.83 (study III) and in MBC: HR 4.29, 95%CI 2.44 – 7.53 
(study IV). 
In conclusion, the current tumor response evaluation criteria are associated with several 
subjective steps that may cause inconsistent results. The initial change in tumor size at the first 
follow-up CT may provide an alternative surrogate outcome. The findings obtained in this 
thesis may improve the development of future response evaluation criteria. 
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